Tuesday, February 24, 2015

Health News

Prevention Possible

Risk of HIV infection reduced by 86%: ANRS IPERGAY study

Released by Kevin Pendergraft, CIHR

 

n ANRS and CIHR Canadian HIV Trials Network (CTN) study shows that taking the drug Truvada ‘on-demand’ before sex reduces risk of HIV infection by 86 per cent among men who have sex with men. 


Unlike other studies that tested the daily use of pre-exposure prophylaxis (PrEP), ANRS IPERGAY tested the intermittent or ‘on demand’ use of Truvada®. Participants randomized to the treatment arm, took two pills in the 24-hour period before anticipated sexual intercourse and two separate one-pill doses in the two days following sex. 


“Health Canada has approved Truvada for the treatment of people living with HIV but it has not been approved for use in prevention. We hope that the results of the ANRS IPERGAY trial and other similar trials will begin to change this,” says Dr. Cécile Tremblay, the Canadian Principal Investigator of the study.  The United States is the only country to approve Truvada for the prevention of HIV infection.


The results of the first phase of the ANRS IPERGAY trial were reported today by Principal Investigator Professor Jean-Michel Molina at the 22nd Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle. The ANRS IPERGAY study builds upon the 2010 iPrEx istudy on the daily use of PrEP which showed a 44 per cent reduction of HIV infection risk.


“This study extends the versatility of PrEP for real-world conditions and adds another prevention tool along with counseling and condoms,” adds Dr. Tremblay.


The ANRS IPERGAY trial was run by the French national AIDS research institute, ANRS, and began in France in February 2012. The CTN joined as a Canadian site in 2013, led by Dr. Cécile Tremblay (Centre hospitalier de l’Université de Montréal (CHUM). In Canada, the study recruited 53 men in Montreal who have sex with men (MSM) into Phase I of the randomized study. In total 414 men participated in the study. The study will continue with open-label ‘on-demand’ Truvada for at least one more year. It is an important step in ensuring the continued long-term benefit of ‘on demand’ PrEP and also assessing the long-term safety.

 

 

About the CIHR Canadian HIV Trials Network:
The CIHR Canadian HIV Trials Network (CTN) is funded by the Canadian Institutes of Health Research (CIHR) and sponsored by the University of British Columbia and St. Paul’s Hospital (Providence Health Care). The CTN is a partnership of clinical investigators, physicians, nurses, people living with HIV, pharmaceutical manufacturers and others committed to developing treatments, vaccines and a cure for HIV and related conditions through the conduct of scientifically sound and ethical clinical trials. The CTN is committed to the pursuits of scientific excellence and ethical integrity in all undertakings. We are also dedicated to working in partnership with the international and national pharmaceutical industry, people living with HIV, researchers and physicians. www.hivnet.ubc.ca 

 

 

© Copyright (c) 2009-2015 The Valley Voice